載入中
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
前收盤價
US$1.02
+US$0.02 · +2.00%
盤中時間採用ET。市場資料可能有所延遲。
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
日內區間
目前US$1.02
52週區間
目前US$1.02
盤中時間採用ET。市場資料可能有所延遲。
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
日內區間
目前US$1.02
52週區間
目前US$1.02
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | 158萬 USD | 968.5萬 USD | 757.2萬 USD |
| 銷貨成本 | 169.6萬 USD | — | — | — | — |
| 毛利 | −169.6萬 USD | — | 158萬 USD | 968.5萬 USD | 757.2萬 USD |
| 研究與開發 | 1.09億 USD | 1.69億 USD | 1.28億 USD | 9693.6萬 USD | 7754.9萬 USD |
| 銷售、一般及管理費用 | 4721.6萬 USD | 5905.5萬 USD | 5792.8萬 USD | 3994.9萬 USD | 2755.8萬 USD |
| 營業費用 | 1.48億 USD | 2.28億 USD | 1.86億 USD | 1.37億 USD | 1.05億 USD |
| 利息收入 | — | 2108.5萬 USD | 2407.6萬 USD | 467萬 USD | 27.2萬 USD |
| 利息支出 | 255.9萬 USD | 302.4萬 USD | 126.7萬 USD | 79.1萬 USD | — |
| 折舊和攤銷 | 169.6萬 USD | 212.5萬 USD | 184.1萬 USD | 182.3萬 USD | 153.5萬 USD |
| 營業利益 | −1.5億 USD | −2.28億 USD | −1.84億 USD | −1.27億 USD | −9753.5萬 USD |
| 淨利 | −1.49億 USD | −2.1億 USD | −1.61億 USD | −1.23億 USD | −9726.3萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$25.86
上漲空間 2435.29%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI192.11萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF67.74萬0.00%954億 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC19.57萬0.01%13.17億 USD0.60%US$183+0.11%
Vanguard Health Care ETFVHT17.11萬0.00%220億 USD0.09%US$319.01+1.64%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM8萬0.07%1.17億 USD0.73%US$15.9402+0.25%
Invesco RAFI US 1500 Small-Mid ETFPRFZ2.22萬0.00%26.7億 USD0.36%US$53.16+0.64%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMInvesco RAFI US 1500 Small-Mid ETFPRFZAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
